A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.

Bauer, Todd M; Patel, Manish R; Forero-Torres, Andres; George, Thomas J; Assad, Albert; Du, Yining; Hurwitz, Herbert

Bauer, Todd M; Patel, Manish R; Forero-Torres, Andres; George, Thomas J; Assad, Albert; Du, Yining; Hurwitz, Herbert.

Afiliación

Bauer TM; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
Patel MR; Medical Oncology, Tennessee Oncology, Nashville, TN, USA.
Forero-Torres A; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
George TJ; Medical Oncology, Florida Cancer Specialists, Sarasota, FL, USA.
Assad A; Hematology and Oncology Division, University of Alabama at Birmingham, Birmingham, AL, USA.
Du Y; Department of Medicine, University of Florida, Gainesville, FL, USA.
Hurwitz H; Biostatistics, Incyte Corporation, Wilmington, DE, USA.

Onco Targets Ther ; 11: 2399-2407, 2018.

Article en En | MEDLINE | ID: mdl-29750040

Palabras clave

Janus kinase inhibitor; pancreatic cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Onco Targets Ther Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google